Approval based on results from phase 3 VIVID-1 trial, in which end points of clinical remission and endoscopic response were met at one year ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

An elemental diet is a medical protocol that replaces food and drinks with liquid formula for people with serious GI ...

Jane Searfoss was inspired to become a child life specialist at Boston Children's Hospital because of her own experience ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...

Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of human interleukin (IL)-23.

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...